Navigation Links
AstraZeneca Initiates Phase 3 Clinical Trial For Selumetinib In Non-Small Cell Lung Cancer
Date:10/22/2013

tabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.

Array BioPharma Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about our potential to earn future milestone and royalty payments under our agreement with AstraZeneca, the potential for the results of ongoing preclinical and clinical trials to support regulatory approval or the marketing success of selumetinib and future plans to progress and develop selumetinib. These statements involve significant risks and uncertainties, including those discussed in our most recent annual report filed on form 10-K, in our quarterly reports filed on Form 10-Q, and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, the ability of AstraZeneca and of Array to meet objectives tied to milestones and royalties; risks associated with our dependence on AstraZeneca for the clinical development and commercialization of selumetinib; AstraZeneca's ability to effectively and timely conduct clinical trials in light of increasing costs and difficulties in locating appropriate trial sites and in enrolling patients who meet the criteria for certain clinical trials; and risks associated with dependence on third-party service providers to successfully conduct clinical trials within and outside the United States. We are providing this information as o
'/>"/>

SOURCE Array BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
2. Clinical Trial Results, Litigation Outcomes and Marketing Authorizations - Research Report on Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Neurocrine
3. Omthera Stockholders Approve Acquisition by AstraZeneca
4. AstraZeneca Neuroscience partners with ePharmaSolutions to optimize Clinical Trial Management
5. Isis Pharmaceuticals Earns $6 Million Payment from AstraZeneca
6. Covington Advises Omthera Pharmaceuticals on Merger with AstraZeneca
7. AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis
8. AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation
9. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
10. Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
11. AstraZeneca And The Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... On Thursday, July 10, 2014, the NASDAQ ... Average finished the day 0.42% lower at 16,915.07, and the ... broad based as eight out of ten sectors ended the ... ended the day at 711.88, down 0.02%, while the index ... initiated coverage on the following equities: Covidien PLC (NYSE: ...
(Date:7/11/2014)... , July 11, 2014 Research ... addition of the "Immunoprotein Diagnostic Testing Market ... the highest CAGR of 6% and is expected ... report to their offering. ... immunoprotein diagnostic testing has been segmented according to ...
(Date:7/11/2014)... LONDON , July 11, 2014 /PRNewswire/ ... of visitors to Safety & Health Expo ... by the move to London ... senior management attending exhibition.     ... (Photo: http://photos.prnewswire.com/prnh/20140711/696892-a ) ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
... NoviPet , a leading global provider of ... supplements for dogs at the Backer,s 24th Annual Pet Industry ... 2012, in Atlantic City, New Jersey. The new dietary ... City Convention Center. NoviPet intends to widen its offerings in the ...
... Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" ... Distribution Specialists, LLC ("HDS") are pleased to announce that ... ("Agreement") with a major pro sports team based in ... of Clotamin.  The Agreement is part of new marketing ...
Cached Medicine Technology:NoviPet to Present New Food Supplements for Dogs at Pet Industry Spring Trade Show 2Sunpeaks Ventures Signs Advertising and Promotion Agreement With Another Major Sports Team - Clotamin To Be Sold at All Walgreens Locations Throughout Arizona 2Sunpeaks Ventures Signs Advertising and Promotion Agreement With Another Major Sports Team - Clotamin To Be Sold at All Walgreens Locations Throughout Arizona 3
(Date:7/14/2014)... Encino, CA (PRWEB) July 14, 2014 ... Dental Group is now offering Lumineers and ... more extensive procedures that require more preparation and greater ... use porcelain tooth-shaped shells to conceal visible flaws on ... Dr. Sabbagh-Fard work closely with patients to ensure they ...
(Date:7/14/2014)... Barbara Bronson Gray ... News) -- New research suggests that a faltering sense ... disease, and that an inexpensive, low-tech smell test could ... In two different studies, the decreased ability to identify ... function and progression to Alzheimer,s disease. "We,re trying ...
(Date:7/14/2014)... Kathleen Doheny HealthDay ... Losing a spouse may be linked to multiple health issues, ... study. For certain seniors, widowhood may even delay dementia, ... memory problem, losing the spouse was associated with a later ... married," said study researcher Dr. Bryan Woodruff. Woodruff, ...
(Date:7/14/2014)... Connecticut (PRWEB) July 14, 2014 ... is celebrating its Grand Opening on Monday, July ... Connecticut 06830. The celebration will last all week ... all new patients. Everyone is welcomed to attend. ... M.D. who provides physician-administered skincare, anti-aging, weight loss ...
(Date:7/14/2014)... Many people are unhappy with their ... to reduce a “double chin.” A new product ... to go under the knife. Jawflex is a double ... therefore tightening the skin in that area and reducing ... used for facial exercise, double chin elimination and sagging ...
Breaking Medicine News(10 mins):Health News:Encino Esthetic Dental Group is Now Offering Lumineers and Porcelain Veneers 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 3Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 3Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 2Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 3Health News:Jawflex | Double Chin Exercise for Double Chin Reduction 2
... BOSTON, Aug. 6 The Center for Business Intelligence (CBI), a ... which includes Dr. Paul Tang, Vice President and Chief Medical Information ... inaugural Access Federal Stimulus Incentives for Electronic Health Records ... in Alexandria, VA, on September 24-25, 2009. , ...
... unaware there is no cure, survey finds , THURSDAY, Aug. ... mistakenly believe that daily medicine can be taken to prevent ... a widespread lack of knowledge and awareness about food allergy ... adults also found that nearly half of respondents incorrectly believed ...
... , , , , ... Wyse Technology , the global leader in thin computing and ... . Kool Smiles is a rapidly-growing company whose mission is ... Since opening its first office in 2002 in Atlanta, GA, the ...
... , , HOUSTON, ... first patient in a Phase I/II clinical trial of BP-GMAX-CD1, a ... cancer. The disease-specific trial is being conducted under a Bellicum Investigational ... anticipates reporting initial results of the study in 2010. , ...
... MCLEAN, Va., Aug. 6 Sunrise Senior Living, Inc. ... data for the second quarter of 2009. Sunrise will host ... a.m. ET, to discuss the financial results. , , ... of progress in expense controls. In recent weeks we have seen ...
... Greece, August 6 , - Not for Release, Publication or Distribution ... Canada, Australia, South Africa or Japan or, any Other ... Unlawful, - This Announcement is not a Prospectus and is not ... Offer to buy any Securities in the United States or, ...
Cached Medicine News:Health News:CBI Announces the Agenda for Their Upcoming Access Federal Stimulus Incentives for Electronic Health Records Conference 2Health News:Food Allergy Facts Need More Focus 2Health News:Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records (EHRs) 2Health News:Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records (EHRs) 3Health News:Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records (EHRs) 4Health News:Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records (EHRs) 5Health News:Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer 2Health News:Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer 3Health News:Sunrise Reports Financial Results for Second-Quarter 2009 2Health News:Sunrise Reports Financial Results for Second-Quarter 2009 3Health News:Sunrise Reports Financial Results for Second-Quarter 2009 4Health News:Sunrise Reports Financial Results for Second-Quarter 2009 5Health News:Sunrise Reports Financial Results for Second-Quarter 2009 6Health News:Sunrise Reports Financial Results for Second-Quarter 2009 7Health News:Sunrise Reports Financial Results for Second-Quarter 2009 8Health News:Sunrise Reports Financial Results for Second-Quarter 2009 9Health News:Sunrise Reports Financial Results for Second-Quarter 2009 10Health News:Sunrise Reports Financial Results for Second-Quarter 2009 11Health News:Sunrise Reports Financial Results for Second-Quarter 2009 12Health News:Sunrise Reports Financial Results for Second-Quarter 2009 13Health News:Sunrise Reports Financial Results for Second-Quarter 2009 14Health News:Sunrise Reports Financial Results for Second-Quarter 2009 15Health News:Sunrise Reports Financial Results for Second-Quarter 2009 16Health News:Sunrise Reports Financial Results for Second-Quarter 2009 17Health News:Sunrise Reports Financial Results for Second-Quarter 2009 18Health News:Sunrise Reports Financial Results for Second-Quarter 2009 19Health News:Sunrise Reports Financial Results for Second-Quarter 2009 20Health News:EANS-News: Alapis Announces its Share Capital Increase to Raise c. EUR 451.1 million 2Health News:EANS-News: Alapis Announces its Share Capital Increase to Raise c. EUR 451.1 million 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: